Patient Preferences for Type 2 Diabetes Mellitus (T2DM) Treatment: A Systematic Review of Discrete Choice Experiments Studies
Author(s)
Hye-In Jung, PharmD1, GaHee Choi, Bachelor's degree1, Dongheui Jang, Master’s degree1, Ha-Jun Song, PharmD1, Hyeonjin Cho, Bachelor's degree1, Sangeun Lee, Bachelor's degree1, Yebin Yoon, PharmD2, Sun-Kyeong Park, PhD, BPharm2, Mi-Hai Park, PhD, BPharm1, Leslie Wilson, BS, MS, RN, PhD3, EUI-KYUNG LEE, PhD, BPharm1.
1Sungkyunkwan University, Suwon, Korea, Republic of, 2The Catholic University of Korea, Bucheon, Korea, Republic of, 3University of California, San Francisco (UCSF), San Francisco, CA, USA.
1Sungkyunkwan University, Suwon, Korea, Republic of, 2The Catholic University of Korea, Bucheon, Korea, Republic of, 3University of California, San Francisco (UCSF), San Francisco, CA, USA.
OBJECTIVES: Type 2 diabetes mellitus (T2DM) requires long-term management. Beyond blood glucose control, factors such as adverse events, conveniences, and costs also influence treatment choices, making patient preferences essential in decision-making. This study aimed to review discrete choice experiment (DCE) studies to examine patient preferences regarding treatment attributes.
METHODS: A systematic review was conducted using PubMed/MEDLINE, EMBASE, and the Cochrane Library for studies published up to May 2025. Three reviewers independently screened and selected studies based on predefined criteria. We extracted data on attribute categories (e.g., efficacy, adverse events, convenience, and cost) and their corresponding attributes. We estimated inclusion frequency for each category and attribute, and the most important attribute. To examine significant differences in how often each attribute was ranked most important, we conducted pairwise Fisher’s Exact Tests for four representative attributes based on their frequency and prominence.
RESULTS: A total of 42 studies were included, all of which evaluated preferences for T2DM medications. Most studies included adverse events (95.2%) and efficacy (92.9%) as attributes. Within efficacy, blood glucose control (51.32%) and weight change (34.21%) were most frequent; within adverse events, hypoglycemia (34.74%) and gastrointestinal side effects (22.11%) were most common. The proportion of studies in which each attribute was rated as most important by patients was: blood glucose control (24.24%), hypoglycemia (19.23%), weight change (15.38%), and gastrointestinal side effects (10.53%). Pairwise Fisher’s Exact Tests indicated no statistically significant differences in the probability of being ranked as the most important among these attributes (all p-values>0.05).
CONCLUSIONS: This review found no significant differences in the importance of key treatment attributes for T2DM. It suggests that patients consider multiple treatment attributes concurrently, underscoring the need for shared decision-making that reflects diverse preferences. Careful consideration is needed when selecting attributes, as their inclusion alone may influence study results.
METHODS: A systematic review was conducted using PubMed/MEDLINE, EMBASE, and the Cochrane Library for studies published up to May 2025. Three reviewers independently screened and selected studies based on predefined criteria. We extracted data on attribute categories (e.g., efficacy, adverse events, convenience, and cost) and their corresponding attributes. We estimated inclusion frequency for each category and attribute, and the most important attribute. To examine significant differences in how often each attribute was ranked most important, we conducted pairwise Fisher’s Exact Tests for four representative attributes based on their frequency and prominence.
RESULTS: A total of 42 studies were included, all of which evaluated preferences for T2DM medications. Most studies included adverse events (95.2%) and efficacy (92.9%) as attributes. Within efficacy, blood glucose control (51.32%) and weight change (34.21%) were most frequent; within adverse events, hypoglycemia (34.74%) and gastrointestinal side effects (22.11%) were most common. The proportion of studies in which each attribute was rated as most important by patients was: blood glucose control (24.24%), hypoglycemia (19.23%), weight change (15.38%), and gastrointestinal side effects (10.53%). Pairwise Fisher’s Exact Tests indicated no statistically significant differences in the probability of being ranked as the most important among these attributes (all p-values>0.05).
CONCLUSIONS: This review found no significant differences in the importance of key treatment attributes for T2DM. It suggests that patients consider multiple treatment attributes concurrently, underscoring the need for shared decision-making that reflects diverse preferences. Careful consideration is needed when selecting attributes, as their inclusion alone may influence study results.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
PCR180
Topic
Methodological & Statistical Research, Patient-Centered Research, Study Approaches
Topic Subcategory
Patient Engagement
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), No Additional Disease & Conditions/Specialized Treatment Areas